Disease relevance of yttrium

• METHODS: After successful balloon angioplasty of a previously untreated coronary stenosis, 181 patients were randomly assigned to receive 9, 12, 15, or 18 Gy of radiation delivered by a centered yttrium-90 source [1].
• Eighty patients were selected from a database of 108 yttrium-90 microsphere-treated patients and were staged by using Child-Pugh, Okuda, and Cancer of the Liver Italian Program scoring systems [2].
• Of 550 patients admitted with acute upper gastrointestinal hemorrhage, 143 with peptic ulcers containing stigmata of recent hemorrhage accessible to endoscopic therapy were included in a randomized comparison of neodymium yttrium aluminum garnet laser, heater probe, and no endoscopic therapy [3].
• Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity [4].
• Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts [5].

Psychiatry related information on yttrium

• To overcome the problem of tumor heterogeneity, we conducted a pilot evaluation of the safety and effectiveness of yttrium 90 (90Y)-labeled anti-Id and shared Id (sId) MoAbs in non-Hodgkin's B-cell lymphoma [6].

High impact information on yttrium

• Endovascular injury was induced in rabbit iliac arteries by ipsilateral balloon angioplasty (BA) and by contralateral balloon angioplasty accompanied by exposure to continuous wave neodymium: yttrium aluminum garnet laser radiation (LBA) [7].
• This article reviews the safety and survival of patients with hepatocellular carcinoma who were treated with yttrium-90 microspheres [2].
• On the basis of these results, a randomized controlled trial is warranted comparing yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of the Liver Italian Program system for prospective stratified randomization [2].
• TheraSphere consists of yttrium-90 (a pure beta emitter) microspheres, which are injected into the hepatic arteries [2].
• Yttrium-90-labelled somatostatin-analogue for cancer treatment [8].

Chemical compound and disease context of yttrium

• Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer [9].
• Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice [10].
• CONCLUSION: (90)Y-hLL2 prepared with the DOTA chelate represents an improved agent for radioimmunotherapy of non-Hodgkin's lymphoma, with an in vivo model demonstrating a large reduction in bone-deposited yttrium, compared with (90)Y-hLL2 agents prepared with open-chain DTPA-type chelating agents [11].
• PURPOSE: To prospectively evaluate the safety and effectiveness of hepatic intraarterial injection of yttrium 90 ((90)Y) tetraazacyclododecane tetraacetic acid (DOTA) lanreotide as a treatment for patients with progressive large-volume somatostatin receptor-positive liver metastases from neuroendocrine tumors [12].
• The two approved radioimmunotherapy agents, yttrium-90 ibritumomab tiuxetan and iodine-131 tositumomab, are being studied in a range of lymphoid malignancies, from low-grade to aggressive B-cell non-Hodgkin's lymphomas [13].

Biological context of yttrium

• Chromosome aberrations and intra-articular yttrium-90 [14].
• Competitive binding assays indicated that the anti-DTPA antibodies reacted with DTPA chelated with indium, yttrium, chromium, iron, or zinc [15].
• Structural dependence of thermodynamics of alkene binding to yttrium alkyl complexes and of kinetics of alkyl migration to coordinated alkenes [16].
• Pharmacokinetics over 7 days, calculated yttrium-90 radiation dosimetry, therapeutic index, and projected maximum tolerated injected yttrium-90 dose were evaluated [17].
• Despite its absence in the structures themselves, control experiments show that carbonate not only functions in the hydrolysis, it also influences the structure of the complexes by complexation to yttrium and the f-block elements [18].

Anatomical context of yttrium

• Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies [6].
• Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease [19].
• Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of the T cell lymphoma EL4 [20].
• In order to clarify effects of ionizing irradiation on synovial cells, radioactive gold (198Au) and yttrium (90Y) were added to fibroblast cultures derived from human synovial membranes [21].
• Animal experiments were performed with evaluation of the use of the neodymium-YAG (yttrium-aluminum-garnet) laser in the trachea, bronchi, and pulmonary parenchyma [22].

Associations of yttrium with other chemical compounds

• Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs [23].
• Atomistic models for CeO(2)(111), (110), and (100) nanoparticles, supported on yttrium-stabilized zirconia [24].
• Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs [25].
• Treatment of the recently reported potassium salt [K(thf)(n)][N(PPh(2))(2)] (n=1.25, 1.5) with anhydrous yttrium or lanthanide trichlorides in THF leads after crystallization from THF/n-pentane (1:2) to the monosubstituted diphosphanylamide complexes [LnCl(2)[(Ph(2)P)(2)N](thf)(3)] (Ln=Y, Sm, Er, Yb) [26].
• Prior to the selective transport of a metal ion through the liquid membrane in the microchannel, the forward and backward extraction of yttrium and zinc ions was investigated in a two-phase flow on a microfluidic device using 2-ethylhexyl phosphonic acid mono-2-ethylhexyl ester (commercial name, PC-88A) as an extractant [27].

Gene context of yttrium

• Experience with indium-111 and yttrium-90-labeled somatostatin analogs [28].
• In the current paper we describe the radiotherapeutic effect of yttrium-90 labelled SMT 487 in Lewis rats bearing the somatostatin receptor-positive rat pancreatic tumour CA 20948 [29].
• Effect of yttrium-90-labeled anti-carcinoembryonic antigen monoclonal antibody on the morphology and phenotype of human tumors grown as peritoneal carcinomatosis in athymic mice [30].
• The mice received intraperitoneal injections of 40 to 160 microCi of yttrium-90 (90Y)-labeled anti-CEA monoclonal antibody (MAb) [30].
• Lack of rise in serum prolactin following yttrium-90 interstitial irradiation for acromegaly [31].

Analytical, diagnostic and therapeutic context of yttrium

• A modified neodymiumdoped yttrium-aluminum-garnet laser operating at a wavelength of 1.319 micrometers was used in conjunction with conventional suture techniques [32].
• The results of a randomised trial of irradiation of the knee (synoviorthése), by intra-articular injection of yttrium-90, and surgical synovectomy have been compared in twenty knees in seventeen patients [33].
• Experimental comparison of endoscopic yttrium-aluminum-garnet laser, electrosurgery, and heater probe for canine gut arterial coagulation. Importance of compression and avoidance of erosion [34].
• Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma [35].
• This phase III randomized study compares the novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control immunotherapy, rituximab, in 143 patients with relapsed or refractory low-grade, follicular, or transformed CD20(+) transformed NHL [36].

References